CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 104 enrolled
Drug / intervention
Riluzole +1 moredrug
Likely dose
Riluzole 100mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01204918
NCT01204918Phase 2Completed
CompareCT.gov

Efficacy and Tolerability of Riluzole in Treatment Resistant Depression

Yale University·interventional·Posted Sep 17, 2010·Updated Mar 6, 2020

In Brief

A Phase 2 clinical trial evaluating Riluzole and placebo for Depression. Completed, enrolled 104 participants across 3 sites.

Detailed Summary

This study aims to examine the antidepressant efficacy of riluzole, employing a randomized, double-blind, placebo-controlled, adjunctive trial in treatment-resistant major depressive disorder (TRD).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDepression
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedSep 17, 2010
Enrollment StartJun 1, 2011
Primary CompletionMay 1, 2015
Study CompletionAug 1, 2015
TodayJul 2, 2026
Enrollment to primary: 3.9 yearsPosted 15.8 years ago

Interventions

Riluzoledrug

Riluzole 100mg PO

placebodrug

placebo